奧貝膽酸

奧貝膽酸
臨床資料
商品名（英語：Drug nomenclature）	Ocaliva
其他名稱	6α-ethyl-chenodeoxycholic acid; INT-747
AHFS/Drugs.com	ocaliva
MedlinePlus	a616033
核准狀況	歐 EMA: yes;
給藥途徑	口服給藥
ATC碼	A05AA04 (WHO) ;
法律規範狀態
法律規範	美：處方藥（℞-only）;
識別資訊
	IUPAC命名法 (3α,5β,6α,7α)-6-Ethyl-3,7-dihydroxycholan-24-oic acid OR (4R)-4-[(3R,5S,6R,7R,8S,9S,10S,13R,14S,17R)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid; ;
CAS號	459789-99-2
PubChem CID	447715;
IUPHAR/BPS	3435;
ChemSpider	394730;
UNII	0462Z4S4OZ;
KEGG	D09360;
ChEBI	CHEBI:43602 ;
ChEMBL	ChEMBL566315;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID20196671 ;
ECHA InfoCard	100.238.318
化學資訊
化學式	C26H44O4
摩爾質量	420.62516 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
熔點	108—110 °C（226—230 °F）
	SMILES CC[C@@H]1[C@@H]2C[C@@H](CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3[C@@H]1O)CC[C@@H]4[C@H](C)CCC(=O)O)C)C)O;
	InChI InChI=1S/C26H44O4/c1-5-17-21-14-16(27)10-12-26(21,4)20-11-13-25(3)18(15(2)6-9-22(28)29)7-8-19(25)23(20)24(17)30/h15-21,23-24,27,30H,5-14H2,1-4H3,(H,28,29)/t15-,16-,17-,18-,19+,20+,21+,23+,24-,25-,26-/m1/s1; Key:ZXERDUOLZKYMJM-ZWECCWDJSA-N;

奧貝膽酸（英語：Obeticholic acid，縮寫OCA，也叫做6α-乙基-鵝去氧膽酸，6α-ethyl-chenodeoxycholic acid，商品名Ocaliva）是一種半合成膽汁酸，用於治療原發性膽汁性膽管炎，後又用於治療幾種肝病。大日本住友製藥擁有此藥在中國和日本的所有權^[2]。

參考文獻

^ Gioiello, Antimo; Macchiarulo, Antonio; Carotti, Andrea; Filipponi, Paolo; Costantino, Gabriele; Rizzo, Giovanni; Adorini, Luciano; Pellicciari, Roberto. Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine. Bioorganic & Medicinal Chemistry. April 2011, 19 (8): 2650–2658. PMID 21459580. doi:10.1016/j.bmc.2011.03.004.
^ Wall Street Journal. A $4 Billion Surprise for 45-Person Biotech. [10 January 2014]. （原始內容存檔於2014-03-28）.

外部連結

Intercept pharmaceuticals. [2019-07-03]. （原始內容存檔於2014-01-10）.
NashBiotechs Several articles on drug candidates in NASH

[1] Gioiello, Antimo; Macchiarulo, Antonio; Carotti, Andrea; Filipponi, Paolo; Costantino, Gabriele; Rizzo, Giovanni; Adorini, Luciano; Pellicciari, Roberto. Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine. Bioorganic & Medicinal Chemistry. April 2011, 19 (8): 2650–2658. PMID 21459580. doi:10.1016/j.bmc.2011.03.004.

[wsj1401-2] Wall Street Journal. A $4 Billion Surprise for 45-Person Biotech. [10 January 2014]. （原始內容存檔於2014-03-28）.

[2]

[1]